All In Biotech

Drug Trial Radar · NCT01132326

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)

A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Last checked: Nov 20, 2026Latest source record: Feb 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Jan 2009

Primary completion

Feb 2013

Study completion Feb 2013

Sponsor

Lead sponsor
Chelsea TherapeuticsIndustry
Sponsor type
Industry
First posted
May 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Symptomatic NOH in patients with primary autonomic failure is thought to be a consequence of norepinephrine depletion leading to a diminished capacity to effect an appropriate cardiovascular response to an orthostatic challenge resulting in symptomatic cerebral-hypoperfusion. Droxidopa augments norepinephrine levels which should lead to improved cerebral perfusion following orthostatic challenge thereby reducing the symptoms of NOH. The present study will evaluate the long-term safety of droxidopa.

Conditions

  • Primary Autonomic Failure
  • Dopamine Beta Hydroxylase Deficiency
  • Non-Diabetic Neuropathy
  • Neurogenic Orthostatic Hypotension

Interventions

  • DroxidopaDrug

    Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients With Treatment-emergent Adverse EventsTime frame: up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.